715 related articles for article (PubMed ID: 30513816)
1. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
Sek K; Mølck C; Stewart GD; Kats L; Darcy PK; Beavis PA
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513816
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
3. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
Front Immunol; 2019; 10():925. PubMed ID: 31244820
[TBL] [Abstract][Full Text] [Related]
4. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
Steingold JM; Hatfield SM
Front Immunol; 2020; 11():570041. PubMed ID: 33117358
[TBL] [Abstract][Full Text] [Related]
5. Adenosinergic signaling as a target for natural killer cell immunotherapy.
Wang J; Matosevic S
J Mol Med (Berl); 2018 Sep; 96(9):903-913. PubMed ID: 30069747
[TBL] [Abstract][Full Text] [Related]
6. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
7. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
8. Targeting adenosine for cancer immunotherapy.
Leone RD; Emens LA
J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
[TBL] [Abstract][Full Text] [Related]
9. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
Hatfield SM; Sitkovsky M
Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
11. Immunoregulatory activity of adenosine and its role in human cancer progression.
Muller-Haegele S; Muller L; Whiteside TL
Expert Rev Clin Immunol; 2014 Jul; 10(7):897-914. PubMed ID: 24871693
[TBL] [Abstract][Full Text] [Related]
12. Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy.
Yang H; Zhang Z; Zhao K; Zhang Y; Yin X; Zhu G; Wang Z; Yan X; Li X; He T; Wang K
Hum Immunol; 2024 May; 85(3):110774. PubMed ID: 38521664
[TBL] [Abstract][Full Text] [Related]
13. CD73 on T Cells Orchestrates Cardiac Wound Healing After Myocardial Infarction by Purinergic Metabolic Reprogramming.
Borg N; Alter C; Görldt N; Jacoby C; Ding Z; Steckel B; Quast C; Bönner F; Friebe D; Temme S; Flögel U; Schrader J
Circulation; 2017 Jul; 136(3):297-313. PubMed ID: 28432149
[TBL] [Abstract][Full Text] [Related]
14. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
15. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
[TBL] [Abstract][Full Text] [Related]
16. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer.
Sek K; Kats LM; Darcy PK; Beavis PA
Curr Opin Pharmacol; 2020 Aug; 53():91-97. PubMed ID: 32854024
[TBL] [Abstract][Full Text] [Related]
18. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Augustin RC; Leone RD; Naing A; Fong L; Bao R; Luke JJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135866
[TBL] [Abstract][Full Text] [Related]
19. Adenosine in cancer immunotherapy: Taking off on a new plane.
Zhang C; Wang K; Wang H
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A
Yu F; Zhu C; Xie Q; Wang Y
J Med Chem; 2020 Nov; 63(21):12196-12212. PubMed ID: 32667814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]